Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study

• Published in: Vaccine 2019-01, Vol.37 (1), p.176-186
• Main Authors: Carmona Martinez, Alfonso, Prymula, Roman, Miranda Valdivieso, Mariano, Otero Reigada, Maria del Carmen, Merino Arribas, Jose Manuel, Brzostek, Jerzy, Szenborn, Leszek, Ruzkova, Renata, Horn, Michael R., Jackowska, Teresa, Centeno-Malfaz, Fernando, Traskine, Magali, Dobbelaere, Kurt, Borys, Dorota
• Format: Article
• Language: English
• Subjects: Age; Antibodies, Bacterial - blood; Antigens; Bacterial Proteins - genetics; Bacterial Proteins - immunology; Capsular polysaccharides; Carrier Proteins - genetics; Carrier Proteins - immunology; Children; Comparators; Conjugates; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage; Disease; Female; Haemophilus influenzae; Hepatitis; Hepatitis B Vaccines - administration & dosage; Humans; Immune response; Immunization, Secondary; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin D - genetics; Immunoglobulin D - immunology; Immunoglobulins; Immunology; Infant; Infants; Infants/children; Licenses; Lipoproteins - genetics; Lipoproteins - immunology; Male; Non-inferiority; PHiD-CV; Pneumococcal conjugate vaccine; Pneumococcal Infections - immunology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - adverse effects; Pneumococcal Vaccines - immunology; Poliovirus Vaccine, Inactivated - administration & dosage; Polysaccharides; Protein D; Proteins; Randomization; Saccharides; Safety; Serogroup; Serotypes; Streptococcus infections; Streptococcus pneumoniae; Tetanus; Vaccines; Vaccines, Combined - administration & dosage; Vaccines, Conjugate - adverse effects; Vaccines, Conjugate - immunology; Whooping cough
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.07.023

•11-/12-valent vaccines include 10 PHiD-CV conjugates + 19A(11v) + 6A(12v) CRM-conjugates.•11vPHiD-CV and 12vPHiD-CV were administered to infants according to a 3 + 1 schedule.•Immunogenicity was compared to PHiD-CV (common serotypes) and PCV13 (19A and 6A).•Post-dose 3 immune responses to investigational vaccines were non-inferior to comparators.•Safety and reactogenicity profiles of 11v/12vPHiD-CV were comparable to that of PHiD-CV. We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRM197-conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent). In this phase II, partially-blind, multicentre study (NCT01204658), healthy infants were randomised (1:1:1:1) to receive 11vPHiD-CV, 12vPHiD-CV, PHiD-CV, or 13-valent CRM197-conjugate pneumococcal vaccine (PCV13), at 2, 3, and 4 (primary series), and 12–15 months of age (booster dose), co-administered with DTPa-HBV-IPV/Hib. Confirmatory objectives assessed non-inferiority of investigational vaccines to comparators (PHiD-CV for common serotypes; PCV13 for 19A and 6A), in terms of percentage of infants with pneumococcal antibody concentrations ≥0.2 μg/mL and antibody geometric mean concentrations, post-primary vaccination. Reactogenicity and safety were assessed. 951 children received ≥1 primary dose, 919 a booster dose. Pre-defined immunological non-inferiority criteria were met simultaneously for 9/11 11vPHiD-CV serotypes (all except 23F and 19A) and 10/12 12vPHiD-CV serotypes (all except 19A and 6A); thus, non-inferiority objectives were reached. For each PHiD-CV serotype, percentages of children with antibody concentrations ≥0.2 µg/mL were ≥96.7% post-primary (except 6B [≥75.2%] and 23F [≥81.1%]), and ≥98.1% post-booster vaccination. For each PHiD-CV serotype except serotype 1, ≥81.0% and ≥93.9% of children had opsonophagocytic activity titres ≥8, post-primary and booster vaccination. AEs incidence was similar across all groups. SAEs were reported for 117 children (29 in the 11vPHiD-CV group, 26 in the 12vPHiD-CV group, 38 in the PHiD-CV group and 24 in the PCV13 group); 4 SAEs were considered vaccination-related. No fatal events were recorded. Addition of 19A and 6A CRM197-conjugates did not alter immunogenicity of the PHiD-CV conjugates; for both investigational vaccines post-booster immune responses to 10 common sero